A randomized trial of CHOP chemotherapy with or without melatonin in patients with favorable prognosis large B-cell lymphoma

Sarma, A.; Rodriguez, Maria Alma; Cabanillas, Fernando; Dang, N. H.; McLaughlin, Peter; Hagemeister, Fredrick B.; Pro, Barbara; Romaguera, Jorge; Younes, Anas; Grimm, Elizabeth A.

doi:10.1200/jco.2004.22.90140.8066

Cited by 5 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We also found that melatonin did not inhibit the cytotoxic action of paclitaxel in 2 relevant cancer cell lines, in agreement with studies using other antioxidants . Treatment of cancer patients with melatonin in several small studies did not impact on the effectiveness of chemotherapy, and a meta‐analysis of 10 randomized controlled trials of over 600 patients with advanced solid tumours reported that melatonin treatment reduced the risk of death at 1 year . Another recent meta‐analysis of 8 trials and 700 patients similarly reported that adjuvant melatonin treatment in patients with cancer resulted in improved 1‐year survival .…”

Section: Discussionsupporting

confidence: 87%

Melatonin limits paclitaxel‐induced mitochondrial dysfunction in vitro and protects against paclitaxel‐induced neuropathic pain in the rat

Galley

McCormick

Wilson

et al. 2017

Journal of Pineal Research

View full text Add to dashboard Cite

Chemotherapy‐induced neuropathic pain is a debilitating and common side effect of cancer treatment. Mitochondrial dysfunction associated with oxidative stress in peripheral nerves has been implicated in the underlying mechanism. We investigated the potential of melatonin, a potent antioxidant that preferentially acts within mitochondria, to reduce mitochondrial damage and neuropathic pain resulting from the chemotherapeutic drug paclitaxel. In vitro, paclitaxel caused a 50% reduction in mitochondrial membrane potential and metabolic rate, independent of concentration (20‐100 μmol/L). Mitochondrial volume was increased dose‐dependently by paclitaxel (200% increase at 100 μmol/L). These effects were prevented by co‐treatment with 1 μmol/L melatonin. Paclitaxel cytotoxicity against cancer cells was not affected by co‐exposure to 1 μmol/L melatonin of either the breast cancer cell line MCF‐7 or the ovarian carcinoma cell line A2780. In a rat model of paclitaxel‐induced painful peripheral neuropathy, pretreatment with oral melatonin (5/10/50 mg/kg), given as a daily bolus dose, was protective, dose‐dependently limiting development of mechanical hypersensitivity (19/43/47% difference from paclitaxel control, respectively). Melatonin (10 mg/kg/day) was similarly effective when administered continuously in drinking water (39% difference). Melatonin also reduced paclitaxel‐induced elevated 8‐isoprostane F2α levels in peripheral nerves (by 22% in sciatic; 41% in saphenous) and limited paclitaxel‐induced reduction in C‐fibre activity‐dependent slowing (by 64%). Notably, melatonin limited the development of mechanical hypersensitivity in both male and female animals (by 50/41%, respectively), and an additive effect was found when melatonin was given with the current treatment, duloxetine (75/62% difference, respectively). Melatonin is therefore a potential treatment to limit the development of painful neuropathy resulting from chemotherapy treatment.

show abstract

Section: Discussionsupporting

confidence: 87%

Melatonin limits paclitaxel‐induced mitochondrial dysfunction in vitro and protects against paclitaxel‐induced neuropathic pain in the rat

Galley

McCormick

Wilson

et al. 2017

Journal of Pineal Research

View full text Add to dashboard Cite

show abstract

“…It was suggested that it exerts a neuroprotective effect that would attenuate the neuropathological changes in the vagal ganglia following a severe hypoxic insult 13. Clinical studies have evaluated the role of melatonin for counteracting chemotherapy-toxicity, particularly myelosuppression and immunosuppression 14–16. Melatonin has been found to inhibit the production of free radicals, which play a part in mediating the toxicity of chemotherapy 14,15.…”

Section: Discussionmentioning

confidence: 99%

“…Other studies specifically evaluating the myeloprotective effect of melatonin when administered with chemotherapy failed to show decrease in the incidence of neutropenia. 16…”

Section: Discussionmentioning

confidence: 99%

“…13 Clinical studies have evaluated the role of melatonin for counteracting chemotherapy-toxicity, particularly myelosuppression and immunosuppression. [14][15][16] Melatonin has been found to inhibit the production of free radicals, which play a part in mediating the toxicity of chemotherapy. 14,15 In a pilot study conducted by Lissoni and colleagues, 14 80 patients with a variety of metastatic solid tumors received chemotherapy with or without melatonin 20 mg daily.…”

Section: Discussionmentioning

confidence: 99%

“…Other studies specifically evaluating the myeloprotective effect of melatonin when administered with chemotherapy failed to show decrease in the incidence of neutropenia. 16 Melatonin has been used safely in previous trials assessing its use in cancer and other patients. [14][15][16][19][20][21][22][23][24] In the two trials by Lissoni and colleagues, there were no adverse effects documented that had increased incidence in patients receiving chemotherapy plus melatonin compared to patients receiving chemotherapy alone.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Melatonin, a Promising Role in Taxane-Related Neuropathy

Nahleh

Pruemer

LaFollette

et al. 2010

Clin Med Insights Oncol

View full text Add to dashboard Cite

Purpose:Melatonin has neuroprotective effects in animal studies and has been suggested to decrease adverse reactions of chemotherapy including neuropathy. This pilot trial aimed at assessing whether melatonin, given during taxane chemotherapy for breast cancer, will decrease the incidence and/or severity of neuropathy.Methods:Twenty two consecutive patients beginning chemotherapy for breast cancer with paclitaxel, or docetaxel were enrolled. Patients received melatonin 21 mg daily at bedtime. Incidence and severity of neuropathy were assessed using neurological examinations, toxicity assessment per NCI-CTC 3.0 scale and FACT-Taxane quality of life questionnaire.Results:Neuropathy was seen in 45% (n = 10) of patients, 23% (n = 6) grade 1 and 22% (n = 5) Grade 2 neuropathy. No grade 3 neuropathies were reported. The majority (55%) of all patients reported no neuropathy. Compliance with melatonin (>60% of dose) was seen in most patients (86%) No patient reported daytime sedation. The median FACT-Taxane quality of life end of study score was 137, with only a 0.5 median decline from baseline.Conclusion:Patients receiving melatonin during taxane chemotherapy had a reduced incidence of neuropathy. Melatonin may be useful in the prevention or reduction of taxane-induced neuropathy and in maintaining quality of life. Larger trials are warranted to further explore the role of melatonin in neuropathy treatment and prevention.

show abstract

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study

Takahashi

Wang

Kantarjian

et al. 2017

The Lancet Oncology

318

245

View full text Add to dashboard Cite

show abstract

A randomized trial of CHOP chemotherapy with or without melatonin in patients with favorable prognosis large B-cell lymphoma

Cited by 5 publications

References 0 publications

Melatonin limits paclitaxel‐induced mitochondrial dysfunction in vitro and protects against paclitaxel‐induced neuropathic pain in the rat

Melatonin limits paclitaxel‐induced mitochondrial dysfunction in vitro and protects against paclitaxel‐induced neuropathic pain in the rat

Melatonin, a Promising Role in Taxane-Related Neuropathy

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study

Contact Info

Product

Resources

About